Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.58 |
| ▸ | CACNA1I | Q9P0X4 | 6/20 | 0.58 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.48 |
| ▸ | CCR2 | P41597 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | RHOC | P08134 | 1/20 | 0.40 |
| ▸ | RHOA | P61586 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277319 | 1.00 | KCNH2 (0.58) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL8371263 | 0.92 | KCNH2 (0.50) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL4271206 | 0.91 | KCNH2 (0.53) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL4285499 | 0.91 | KCNH2 (0.53) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL4271210 | 0.91 | KCNH2 (0.53) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL7799664 | 0.90 | KCNH2 (0.57) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL4284282 | 0.89 | KCNH2 (0.46) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL4284288 | 0.89 | KCNH2 (0.46) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL4280347 | 0.89 | KCNH2 (0.60) | KCNH2CACNA1IMCHR1CCR2HTR1A | |
| SCHEMBL4280345 | 0.89 | KCNH2 (0.60) | KCNH2CACNA1IMCHR1CCR2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298834-A1 | 4-(AMINOMETHYL)CYCLOHEXANAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1I, CACNA1H | KCNH2 46/4885CACNA1I 2/4885MCHR1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.